Compare LSTA & RAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LSTA | RAND |
|---|---|---|
| Founded | 1980 | 1969 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Health and Biotechnology Services | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.9M | 31.8M |
| IPO Year | 2000 | 1996 |
| Metric | LSTA | RAND |
|---|---|---|
| Price | $3.46 | $10.15 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | ★ 95.1K | 3.7K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 10.83% |
| EPS Growth | ★ 20.42 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $35,283,868.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 56.90 | N/A |
| 52 Week Low | $1.81 | $10.00 |
| 52 Week High | $5.07 | $20.00 |
| Indicator | LSTA | RAND |
|---|---|---|
| Relative Strength Index (RSI) | 55.17 | 39.61 |
| Support Level | $3.06 | $10.05 |
| Resistance Level | $3.67 | $11.15 |
| Average True Range (ATR) | 0.18 | 0.24 |
| MACD | 0.05 | -0.06 |
| Stochastic Oscillator | 47.87 | 8.11 |
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. Its investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.